What We're Reading: Page 228
Industry reads hand-picked by our editors
Feb 20, 2019
Feb 19, 2019
-
Reuters
Philippines revokes Sanofi's product license for dengue vaccine
-
The New York Times
As McKinsey Sells Advice, Its Hedge Fund May Have a Stake in the Outcome
-
Reuters
As medical costs mount, Japan to weigh cost-effectiveness in setting drug prices
-
Axios
Blockbuster drugs are stacking up orphan approvals
Feb 15, 2019
Feb 14, 2019
-
Law360
Insys thought it 'owned' doctors, former CEO testifies
-
CNBC
Pfizer still holds the lead in the erectile dysfunction market even as Viagra sales falter
-
Bloomberg
Biotech hedge fund bailed on drugmaker before its depression treatment scored
-
The Washington Post
The Sacklers have donated millions to museums. But their connection to the opioid crisis is threatening that legacy.
Feb 13, 2019
-
The Boston Globe
Former CEO says Insys founder pushed for higher doses of opioid
-
Kaiser Health News
Americans Cross Border Into Mexico To Buy Insulin At A Fraction Of U.S. Cost
-
The New York Times
Trump Pledged to End H.I.V. But His Policies Veer the Other Way.
Feb 12, 2019
-
STAT
How can we make the J.P. Morgan Healthcare Conference better?
-
Nature
An audience with Hal Barron
-
Kaiser Health News
A 'Fountain Of Youth' Pill? Sure, If You're A Mouse.
-
The Wall Street Journal
FDA Challenges Supplement Makers' Marketing Claims
Feb 11, 2019
-
Nature
Stock price effects of breakthrough therapy designation
-
Bloomberg
China's potential HIV contamination revives drug safety fears
-
The Wall Street Journal
24-Hour Flu Pill May Not Be Miracle Drug Doctors Thought
-
Nikkei Asian Review
Biotech startup turns palm waste into high-value chemicals
-
The Washington Post
Unvaccinated teens are fact-checking their parents — and trying to get shots on their own
Previous
